title: Assessing the immunological response to hepatitis B vaccination in HIV-infected patients in clinical practice.
abstract: Hepatitis B vaccination is recommended in HIV-infected patients. Achieving seroprotection rates (anti-HBs ≥ 10I U/L) comparable to the general population remains a challenge. The aim of this study was to analyze the proportion of responders among patients infected with HIV receiving primary HBV vaccination and identify factors associated with seroprotection rates. We analyzed the response to vaccination (antiHBs titers) in 474 HIV-infected patients receiving ≥ 1 doses of vaccine between 1994 and 2009. Factors associated with response to vaccination were analyzed using a logistic regression model. Considering the first vaccine courses administered, a response rate of 60.3% (286/474) was obtained. Eighty-seven patients began a second course, responding in 58.6% of cases. Regardless of the number of doses, schedules, and whether or not they completed the course, the response rates were 71.1% (337/474). After adjustment for year of reception of the first dose, responders were less likely to have a higher baseline HIV 1-RNA viral load (OR: 0.78 95% CI: 0.68-0.91) and more likely to have a CD4 count ≥ 350 cells/μL (OR: 1.64, 95% CI: 1.03-3.62). Patients receiving less than three doses of vaccine (OR: 0.31 95% CI 0.15-0.61) or three doses of the rapidly accelerated schedule (OR: 0.35 95% CI 0.15-0.81) had a lower probability of response in comparison with those receiving three doses of an accelerated schedule. In patients diagnosed with HIV, HBV vaccination before evolution to greater immunosuppression (CD4 < 350 cells/μL) or delaying vaccination until the CD4 count is higher could provide better seroprotection rates. The rapidly accelerated vaccination schedule should be used with caution, due to its lower effectiveness. If seroprotection is not achieved after the first course, revaccination seems to be effective in increasing the proportion of responders.
authors.affiliation: Preventive Medicine and Epidemiology Unit, Hospital Clínic, c/Villarroel 174, 08036 Barcelona, Spain. gmena@clinic.ub.es
authors.forename: Guillermo
authors.initials: G
authors.lastname: Mena
authors.forename: Anna
authors.initials: A
authors.lastname: Llupià
authors.forename: Alberto L
authors.initials: AL
authors.lastname: García-Basteiro
authors.forename: Consolación
authors.initials: C
authors.lastname: Díez
authors.forename: Agathe
authors.initials: A
authors.lastname: León
authors.forename: Felipe
authors.initials: F
authors.lastname: García
authors.forename: José M
authors.initials: JM
authors.lastname: Bayas
mesh_terms: D000328:Adult; D018791:CD4 Lymphocyte Count; D005260:Female; D015658:HIV Infections / Q000276:immunology*; D015497:HIV-1 / Q000302:isolation & purification; D006509:Hepatitis B / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000097:blood*; D017325:Hepatitis B Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D006801:Humans; D008297:Male; D014611:Vaccination / Q000379:methods*; D019562:Viral Load
chemical_list: D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines